A study Bavituximab and Pembrolizumab for progressive recurrent/metastatic squamous cell carcinoma of the head and neck

Trial Profile

A study Bavituximab and Pembrolizumab for progressive recurrent/metastatic squamous cell carcinoma of the head and neck

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Bavituximab (Primary) ; Pembrolizumab
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jul 2017 According to a Peregrine Pharmaceuticals media release, this trial is expected to be initiated by the end of the calendar year 2017.
    • 13 Mar 2017 This trial is on track to be initiated by mid-calendar 2017, according to a Peregrine Pharmaceuticals media release.
    • 23 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top